You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Model populationPlease check if "Tables 1-6 data" were presented correctly.The data in these tables are correct. We have changed the formatting of the tables to make them easier to readPlease left align text in the left column of table 6.

From: The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries

Parameter Spain Sweden UK
Prevalence
 Total number of individuals aged ≥18 (n) 37,860,506 [36] 7,772,932 [37] 50,909,098 [38]
 Prevalence of diagnosed asthma (%) 3.5 [39] 8.0 [41] 6.1 [42]
 Prevalence of diagnosed COPD (%) 2.8 [40] 7.0 [43] 1.8 [42]
Proportion of patients receiving ICS + LABA FDCs (%)
 Asthma 33.4 [39] 50.0 [41] 35.5 [44]
 COPD 33.7 [40] 39.7 [43] 35.5a
Proportion of patients using commonly prescribed DPIs to administer ICS + LABA FDCs (%)
 BF Turbuhaler® 34.6 [30] 74.7 [59] 31.1 [30]
 FS Accuhaler® 37.3 [30] 15.1 [59] 25.2 [30]
Prescription distribution of BF Turbuhaler® doses (%)
 BF Turbuhaler® 80/4.5 μg 3.4 [30] 1.1 [30] 8.6 [30]
 BF Turbuhaler® 160/4.5 μg 54.0 [30] 48.5 [30] 55.9 [30]
 BF Turbuhaler® 320/9 μg 42.7 [30] 50.4 [30] 35.5 [30]
Prescription distribution of FS Accuhaler® doses (%)
 FS Accuhaler® 100 μg 5.9 [30] 3.8 [30] 11.5 [30]
 FS Accuhaler® 250 μg 40.1 [30] 50.3 [30] 25.5 [30]
 FS Accuhaler® 500 μg 54.0 [30] 45.9 [30] 63.0 [30]
  1. BF Turbuhaler® is marketed as Symbicort® Turbohaler® in the UK, and Symbicort® Turbuhaler® in Spain and Sweden; FS Accuhaler® is marketed as Seretide® Accuhaler® in Spain and the UK, and Seretide® Diskus® in Sweden. Values are subject to rounding
  2. aAssumed to be equal to proportion of asthma patients